30/07/2026 CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases Pfizer announced topline Phase 3 results for LITFULO in Patients with Nonsegmental Vitiligo CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases (Ref) CREATE Medicines announced that it had received Human Research Ethics Committee (HREC) approval in Australia to begin its Phase